Mirum Pharmaceuticals, Inc. (MIRM) saw its stock price soar 5.26% during intraday trading on Wednesday. The significant upward movement follows the company's recent corporate and clinical developments.

The biopharmaceutical company successfully priced a $600 million private offering of 0% convertible senior notes due in 2032. The initial conversion price was set at $138.94, representing a substantial 30% premium to the stock's previous closing price. Mirum plans to use approximately $475 million of the net proceeds to repurchase a portion of its outstanding 4% convertible notes due in 2029, effectively refinancing higher-cost debt, with the remainder allocated for general corporate purposes.

Investor sentiment was further bolstered by recent positive clinical news. Last week, the company announced that its rare liver disease drug, volixibat, met its main goal in a mid-stage study. Additionally, all 11 analysts covering the stock maintain bullish ratings, including four "strong buy" recommendations, with a median price target of $140 according to recent data.